Literature DB >> 3123275

Persistent ovarian cysts following administration of human menopausal and chorionic gonadotropins: an attenuated form of ovarian hyperstimulation syndrome.

I S Tummon1, I Henig, E Radwanska, Z Binor, R Rawlins, W P Dmowski.   

Abstract

Ovarian cysts persisting after the onset of menses were demonstrated by ultrasound (US) in 40 of 71 (56%) nonconception cycles following ovulation induction with human menopausal gonadotropins (hMG) and human chorionic gonadotropin (hCG). Persistent cysts were self-limited and all resolved spontaneously within two cycles. They developed more frequently during stimulation cycles with (1) higher mean pre-hCG serum estradiol (E2), (2) a greater number of medium and large follicles at peak pre-hCG E2, and (3) a larger leading follicle diameter at peak pre-hCG E2. Persistent ovarian cysts frequently occurred despite a peak pre-hCG E2 lower than 1000 pg/ml. Although ovarian enlargement in the presence of cysts exceeded 5 X 5 cm in 25% of cases, no patient developed clinical symptoms of ovarian hyperstimulation syndrome (OHSS). Repeated induction of ovulation with hMG/hCG in the presence of nonfunctional, persistent cysts resulted in pregnancies in 6 of 15 cases (40%). Asymptomatic persistent ovarian cysts frequently follow an hMG/hCG regimen and, when nonfunctional, are not a contraindication to repeated ovarian stimulation. Persistent ovarian cysts appear to be an attenuated form of OHSS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123275     DOI: 10.1016/s0015-0282(16)59710-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Ovarian cyst aspiration prior to initiating ovarian hyperstimulation for in vitro fertilization.

Authors:  K M Silverberg; D L Olive; R S Schenken
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-06

2.  Current trends in the treatment of polycystic ovary syndrome with desire for children.

Authors:  Margalida E Sastre; Maria O Prat; Miguel Angel Checa; Ramon C Carreras
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.